Breaking News, Collaborations & Alliances

Sartorius Stedim Biotech, Nanotein Technologies to Advance Cell Therapy Manufacturing

Sartorius supports commercialization and joint development of solutions based on Nanotein’s NanoSpark platform.

By: Rachel Klemovitch

Assistant Editor

Sartorius Stedim Biotech, a partner to the biopharmaceutical industry, and Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered a manufacturing and distribution partnership.  As part of the collaboration, Sartorius will invest up to $3 million in a minority shareholding in Nanotein Technologies to support the commercialization and joint development of solutions based on its NanoSpark platform. Under the exclusive distribution agreement, Sartor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters